Hims & Hers Health, Inc. Earnings Recaps
Q1 2026
May 13, 2026
Shares dropped 11.5% following earnings as investors reacted negatively to a cautious outlook on growth and margin pressures despite commentary on platform expansion and new product introductions.
Key takeaways
- Management highlighted progress in expanding therapeutic specialties and strategic initiatives, including a shift in the weight loss business towards a broader, globally unified approach.
- Adoption of GLP-1 products, including over 125,000 shipments of Wegovy within six weeks, showed initial demand strength but did not offset broader investor concerns.
- Expansion efforts include a planned acquisition of Eucalyptus to enhance global footprint across key markets like Australia, the U.K., Germany, Japan, and Canada.
- The company emphasized investments in data and technology, aiming for longer-term platform engagement and network effects.
- Despite these positives, investor reaction suggests skepticism about near-term growth acceleration and margin sustainability, as reflected in the significant decline in share price.
Q3 2025
Nov 4, 2025
Hims & Hers reported a robust Q3 2025, achieving nearly 50% year-over-year revenue growth driven by a 50% increase in subscribers using personalized health solutions, bolstered by strategic partnerships and innovations.
Key takeaways
- Subscribers utilizing personalized care solutions surged 50% year-over-year, underpinning revenue growth.
- Strategic partnerships with Novo Nordisk and Marius Pharmaceuticals aim to expand access to innovative treatments, including Wegovy.
- The company made a significant investment in GRAIL, enhancing its offerings in multi-cancer early detection.
- A strategic reduction in GLP-1 treatment prices by up to 20% aims to broaden care accessibility.
- Ongoing verticalization of compounding operations is expected to improve efficiency and quality in service delivery.